By: BRIELLE BENYON From: oncnursingnews.com The advent of CDK4/6 inhibitors has caused landmark change in the treatment and outcomes of patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer. Three agents were already on the market – palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) – with a fourth, alpelisib (Piqray), approved this May. This could change the space even more …
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
Source: GLOBE NEWSWIRE From: yahoo.com 226 patients with metastatic breast cancer have been enrolled in the AIPAC study Combination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with chemotherapy is designed to boost the T-cell immune responses against tumours Read-out of progression-free survival (PFS) primary endpoint expected to occur in Q1 of calendar year 2020 Immutep …
Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer
From: biospace.com Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial. Polyphor today announced the enrollment of the first patient in its FORTRESS clinical trial, the pivotal Phase III study evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer …
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
Source: Celsion CORP From: globenewswire.com An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range of Solid Tumors with Multiple Localized Heating Sources Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in …
Phase III NALA Trial Results in Higher PFS With Neratinib Combo for HER2+ Breast Cancer
By: Jason M. Broderick From: targetedonc.com Combining Neratinib (Nerlynx) with capecitabine (Xeloda) showed a 24% reduction in the risk of disease progression or death compared with lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer who had previously received 2 lines of HER2-targeted therapy, according to the results of the phase III NALA trial presented at the 2019 …
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced additional details of the results from the Phase 3 SOPHIA study of margetuximab in patients with …
Metastatic Breast Cancer Genomes Point to Distinct Features, Tumor Evolution
By: Staff Reporter From: genomeweb.com A team from France, Switzerland, and the US has characterized genomic alterations that are specific to advanced, metastatic forms of breast cancer using exome sequence and clinical outcome data. As they reported online today in Nature, the researchers did whole-exome sequencing on samples from more than 600 individuals with metastatic breast cancer, identifying alterations that …
McSally’s bill would hasten health coverage for metastatic breast cancer patients
By: Ripon Advance News Service From: riponadvance.com U.S. Sen. Martha McSally (R-AZ) on May 8 sponsored bipartisan legislation that would eliminate the waiting periods for disability insurance benefits and Medicare coverage for Americans having metastatic breast cancer. “Breast cancer patients don’t have time to wait months or even years to access treatment,” Sen. McSally said. “My bill would waive these …
CDK4/6 Inhibitors Firmly Established in HR+ Breast Cancer, OS Data Awaited
By: Gina Columbus From: onclive.com The improvement in progression-free survival (PFS) that has been observed with CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer has led to changes in clinical practice. However, physicians are still awaiting further overall survival (OS) findings that will solidify the use of these agents, said Daphne B. Stewart, MD. Thus far, …
AstraZeneca, Daiichi Sankyo’s $6.9B breast cancer drug partnership bears fruit in less than two months
By: Alaric DeArment From: medcitynews.com The companies announced the partnership in March to develop trastuzumab deruxtecan, for which they plan to file approval later this year based on the successful Phase II study. The growing field of antibody-drug conjugates may soon get a new member with positive Phase II data in breast cancer. Anglo-Swedish drugmaker AstraZeneca and Japan-based Daiichi …